FluGen announced today it has dosed its first patients in a clinical trial of a novel investigational influenza vaccine called M2SR against multi-season mismatched strains, in Belgium.

“If successful, the results from this challenge study of (our) vaccine would represent a significant step forward in bringing a novel influenza vaccine to patients and which responds to the need for broader protection and increased effectiveness, as compared to existing influenza vaccine options,” FluGen CEO Paul Radspinner said in a statement.

According to a release, the subjects will be followed on an ongoing basis for four months, with a target enrollment for the study at 96 people. As previously reported, half of the trial participants will receive a placebo and the other will get FluGen’s vaccine.

The Department of Defense is supporting the study with its $14.4 million grant.